{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T06:44:36Z","timestamp":1790750676826,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sildenafil is widely used off-label in pediatric patients with pulmonary arterial hypertension (PAH). This study was conducted to characterize the pharmacokinetics (PK) of sildenafil in term and preterm neonates with PAH, by developing a population PK model, and to suggest appropriate doses to achieve clinically effective concentrations. A population PK modelling analysis was performed using sildenafil and its metabolite N-desmethyl sildenafil (DMS) concentration data from 19 neonates with PAH, whose gestational ages ranged 24\u201341\u00a0weeks. They received sildenafil orally at a dose of 0.5\u20130.75\u00a0mg\/kg, four times a day. To investigate the appropriate sildenafil dose, simulations were conducted according to body weight which was significant covariate for sildenafil clearance. A one-compartment model with first-order absorption adequately described the PKs of sildenafil and DMS. Sildenafil clearance was expected to increase rapidly with increasing body weight. In the simulation, sildenafil doses\u2009&gt;\u20091\u00a0mg\/kg was required to achieve and maintain target concentrations of sildenafil and to expect timely clinical effects in term and preterm infants. These results could be utilized for the safer and more effective use of sildenafil in term and preterm infants.<\/jats:p>","DOI":"10.1038\/s41598-022-11038-6","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T16:09:17Z","timestamp":1651766957000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Population pharmacokinetic analysis of sildenafil in term and preterm infants with pulmonary arterial hypertension"],"prefix":"10.1038","volume":"12","author":[{"given":"Su-jin","family":"Rhee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Han","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaeseong","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Hwa","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Won","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"key":"11038_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1586\/ers.09.16","volume":"3","author":"C Tissot","year":"2009","unstructured":"Tissot, C. & Beghetti, M. Advances in therapies for pediatric pulmonary arterial hypertension. Expert. Rev. Respir. Med. 3, 265\u2013282 (2009).","journal-title":"Expert. Rev. Respir. Med."},{"key":"11038_CR2","first-page":"157","volume":"16","author":"P Bendapudi","year":"2015","unstructured":"Bendapudi, P., Rao, G. G. & Greenougm, A. Diagnosis and management of persistent pulmonary hypertension of the newborn. Paediatr. Respir. Rev. 16, 157\u2013161 (2015).","journal-title":"Paediatr. Respir. Rev."},{"key":"11038_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1055\/s-0029-1233306","volume":"30","author":"MM Hoeper","year":"2009","unstructured":"Hoeper, M. M. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin. Respir. Crit. Care Med. 30, 369\u2013375 (2009).","journal-title":"Semin. Respir. Crit. Care Med."},{"key":"11038_CR4","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1097\/PCC.0b013e3181c76cdc","volume":"11","author":"RH Steinhorn","year":"2010","unstructured":"Steinhorn, R. H. Neonatal pulmonary hypertension. Pediatr. Crit. Care Med. 11, S79-84 (2010).","journal-title":"Pediatr. Crit. Care Med."},{"key":"11038_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4103\/0022-3859.159421","volume":"61","author":"AK Dhariwal","year":"2015","unstructured":"Dhariwal, A. K. & Bavdekar, S. B. Sildenafil in pediatric pulmonary arterial hypertension. J. Postgrad. Med. 61, 181\u2013192 (2015).","journal-title":"J. Postgrad. Med."},{"key":"11038_CR6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1586\/ers.09.71","volume":"4","author":"TP Singh","year":"2010","unstructured":"Singh, T. P. Clinical use of sildenafil in pulmonary artery hypertension. Expert. Rev. Respir. Med. 4, 13\u201319 (2010).","journal-title":"Expert. Rev. Respir. Med."},{"key":"11038_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1378\/chest.125.2.580","volume":"125","author":"HH Leuchte","year":"2004","unstructured":"Leuchte, H. H. et al. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 125, 580\u2013586 (2004).","journal-title":"Chest"},{"key":"11038_CR8","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrd2030","volume":"5","author":"HA Ghofrani","year":"2006","unstructured":"Ghofrani, H. A., Osterloh, I. H. & Grimminger, F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 5, 689\u2013702 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"11038_CR9","unstructured":"U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA clarifies Warning about Pediatric Use of Revatio (sildenafil) for Pulmonary Arterial Hypertension. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-clarifies-warning-about-pediatric-use-revatio-sildenafil-pulmonary (2014)"},{"key":"11038_CR10","unstructured":"London, UK: European Medicines Agency. European Medicines Agency. Assessment report for Revatio. International non-proprietary name: Sildenafil. Procedure No. EMEA\/H\/C\/000638\/II\/0028. https:\/\/www.ema.europa.eu\/en\/documents\/variation-report\/revatio-h-c-638-ii-0028-epar-assessment-report-variation_en.pdf (2011)."},{"key":"11038_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1157\/13098935","volume":"66","author":"A Sola","year":"2007","unstructured":"Sola, A. & Baquero, H. Sildenafilo oral en medicina neonatal \u201cInvestigado para adultos, usado tambi\u00e9n por neonatos\u201d [Oral sildenafil in neonatal medicine: \u201ctested in adults also used in neonates\u201d]. An Pediatr. (Barc). 66, 167\u2013176 (2007).","journal-title":"An Pediatr. (Barc)."},{"key":"11038_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00431-019-03556-9","volume":"179","author":"L Schrier","year":"2020","unstructured":"Schrier, L. et al. Off-label use of medicines in neonates, infants, children, and adolescents: A joint policy statement by the European Academy of Paediatrics and the European society for Developmental Perinatal and Pediatric Pharmacology. Eur. J. Pediatr. 179, 839\u2013847 (2020).","journal-title":"Eur. J. Pediatr."},{"key":"11038_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/clpt.2008.177","volume":"85","author":"A Mukherjee","year":"2009","unstructured":"Mukherjee, A., Dombi, T., Wittke, B. & Lalonde, R. Population pharmacokinetics of sildenafil in term neonates: Evidence of rapid maturation of metabolic clearance in the early postnatal period. Clin Pharmacol Ther. 85, 56\u201363 (2009).","journal-title":"Clin Pharmacol Ther."},{"key":"11038_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","volume":"125","author":"RJ Barst","year":"2012","unstructured":"Barst, R. J. et al. A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension. Circulation 125, 324\u2013334 (2012).","journal-title":"Circulation"},{"key":"11038_CR15","doi-asserted-by":"publisher","first-page":"F109","DOI":"10.1136\/adc.2009.168336","volume":"95","author":"MJ Ahsman","year":"2010","unstructured":"Ahsman, M. J. et al. Sildenafil exposure in neonates with pulmonary hypertension after administration via a nasogastric tube. Arch. Dis. Child Fetal Neonatal. Ed. 95, F109-114 (2010).","journal-title":"Arch. Dis. Child Fetal Neonatal. Ed."},{"key":"11038_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1038\/sj.ijir.3901522","volume":"19","author":"N Mehrotra","year":"2007","unstructured":"Mehrotra, N., Gupta, M., Kovar, A. & Meibohm, B. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int. J. Impot. Res. 19, 253\u2013264 (2007).","journal-title":"Int. J. Impot. Res."},{"key":"11038_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamainternmed.2015.6058","volume":"176","author":"T Eguale","year":"2016","unstructured":"Eguale, T. et al. Association of off-label drug use and adverse drug events in an adult population. JAMA Intern Med. 176, 55\u201363 (2016).","journal-title":"JAMA Intern Med."},{"key":"11038_CR18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00246-009-9523-1","volume":"30","author":"AJ Huddleston","year":"2009","unstructured":"Huddleston, A. J., Knoderer, C. A., Morris, J. L. & Ebenroth, E. S. Sildenafil for the treatment of pulmonary hypertension in pediatric patients. Pediatr. Cardiol. 30, 871\u2013882 (2009).","journal-title":"Pediatr. Cardiol."},{"key":"11038_CR19","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1111\/bcp.14111","volume":"85","author":"D Gonzalez","year":"2019","unstructured":"Gonzalez, D. et al. Best Pharmaceuticals for Children Act - Pediatric Trials Network Steering Committee: Population pharmacokinetics of sildenafil in extremely premature infants. Br. J. Clin. Pharmacol. 85, 2824\u20132837 (2019).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"11038_CR20","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/jp.2016.79","volume":"36","author":"N Thakkar","year":"2016","unstructured":"Thakkar, N. et al. An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants. J. Perinatol. 36, 744\u2013747 (2016).","journal-title":"J. Perinatol."},{"key":"11038_CR21","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00228-019-02767-1","volume":"76","author":"SCM Cochius-den Otter","year":"2020","unstructured":"Cochius-den Otter, S. C. M. et al. Pharmacokinetic modeling of intravenous sildenafil in newborns with congenital diaphragmatic hernia. Eur. J. Clin. Pharmacol. 76, 219\u2013227 (2020).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"11038_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/23808993.2016.1138845","volume":"1","author":"DB Hawcutt","year":"2016","unstructured":"Hawcutt, D. B., Cooney, L., Oni, L. & Pirmohamed, M. Precision dosing in children. Expert Rev. Precis. Med. Drug Dev. 1, 69\u201378 (2016).","journal-title":"Expert Rev. Precis. Med. Drug Dev."},{"key":"11038_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40262-014-0134-5","volume":"53","author":"I Mahmood","year":"2014","unstructured":"Mahmood, I. Dosing in children: A critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings. Clin. Pharmacokinet. 53, 327\u2013346 (2014).","journal-title":"Clin. Pharmacokinet."},{"key":"11038_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/hep.1840380424","volume":"38","author":"R Wolbold","year":"2003","unstructured":"Wolbold, R. et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38, 978\u2013988 (2003).","journal-title":"Hepatology"},{"key":"11038_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1124\/mol.109.056705","volume":"76","author":"DJ Waxman","year":"2009","unstructured":"Waxman, D. J. & Holloway, M. G. Sex differences in the expression of hepatic drug metabolizing enzymes. Mol. Pharmacol. 76, 215\u2013228 (2009).","journal-title":"Mol. Pharmacol."},{"key":"11038_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.2165\/00003495-199550020-00003","volume":"50","author":"RZ Harris","year":"1995","unstructured":"Harris, R. Z., Benet, L. Z. & Schwartz, J. B. Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50, 222\u2013239 (1995).","journal-title":"Drugs"},{"key":"11038_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.2165\/00003088-200241050-00002","volume":"41","author":"B Meibohm","year":"2002","unstructured":"Meibohm, B., Beierle, I. & Derendorf, H. How important are gender differences in pharmacokinetics?. Clin. Pharmacokinet. 41, 329\u2013342 (2002).","journal-title":"Clin. Pharmacokinet."},{"key":"11038_CR28","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1067\/mcp.2002.128388","volume":"72","author":"CL Cummins","year":"2002","unstructured":"Cummins, C. L., Wu, C. Y. & Benet, L. Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72, 474\u2013489 (2002).","journal-title":"Clin. Pharmacol. Ther."},{"key":"11038_CR29","doi-asserted-by":"publisher","first-page":"21S","DOI":"10.1046\/j.0306-5251.2001.00029.x","volume":"1","author":"GJ Muirhead","year":"2002","unstructured":"Muirhead, G. J., Wilner, K., Colburn, W., Haug-Pihale, G. & Rouviex, B. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil. Br. J. Clin. Pharmacol. 1, 21S-30S (2002).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"11038_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1432-1033.1997.00625.x","volume":"247","author":"D Lacroix","year":"1997","unstructured":"Lacroix, D., Sonnier, M., Moncion, A., Cheron, G. & Cresteil, T. Expression of CYP3A in the human liver\u2013evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur J Biochem. 247, 625\u2013634 (1997).","journal-title":"Eur J Biochem."},{"key":"11038_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1124\/jpet.103.060137","volume":"308","author":"SB Koukouritaki","year":"2004","unstructured":"Koukouritaki, S. B. et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J. Pharmacol. Exp. Ther. 308, 965\u2013974 (2004).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"11038_CR32","unstructured":"U.S. Food and Drug Administration. REVATIO (sildenafil) Label. Reference ID: 3471998. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021845s008lbl.pdf (2014)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11038-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11038-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T21:39:48Z","timestamp":1669325988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-11038-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["11038"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-11038-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"30 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7393"}}